The C5 blocking monoclonal antibody (mAb) eculizumab has been successfully used for PNH for >10 years and a specific C5aR1 antagonist (avacopan) has been filed for Food and Drug Administration approval for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis. Here, C5AR1 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.